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facteurs prédictifs d'une infection à CMV prolongée chez les 
transplantés d'organes solides 
MISE Ef\I PERSPECTIVE : On observe fréquemment chez les transplantés 
d' organe solide (greffés) des infections récurrentes à CM V après un 
premier traitement. Notre étude consiste à décrire le cours d'une 
infection à CM V chez les greffés et d'identifier les facteurs prédictifs 
d'une infection prolongée avec des récidives. 
METHODES : A l'aide d'une PCR quantitative, nous avons analysé 
rétrospectivement dans les leucocytes et dans le plasma la variation 
longitudinale de la charge virale en Df\IA de CM V chez les greffés donbt 
l'infection à CM V avait été prise en charge d'une manière thérapeutique ou 
préemptive, sur la base de cultures sanguines quantitatives. 
RESULTATS: Parmi les 101 patients greffés (cœur, foie, rein), 63 ont 
présenté au moins un épisode infectieux à CM V, dont 32 ont développé des 
récidives. Chez les patients ayant présentés des infections récurrentes, 
l'analyse du taux de Df\IA de CM V dans le sang périphérique et le plasma a 
montré que la majorité (27) de ces patients avait une charge virale élevée 
pendant une période prolongée (~ 1 mois), malgré un traitement préemptif 
ou thérapeutique. Les facteurs prédictifs d'une infection prolongée se 
sont avérés être l'âge, la séropositivité pour CM V du donneur, et toutes les 
mesures de la charge virale pendant l'épisode infectieux initial. La 
séropositivité pour CM V du receveur protègeait fortement contre une 
infection prolongée. Le taux de Df\IA à CM V dans le plasma à la fin d'un 
traitement permettait au mieux de distinguer les patients développant ou 
pas une infection prolongée. 
COf\ICLUSIOf\IS : Chez les patients transplantés d'un organe solide, 
l'infection prolongée à CM V est associée à l'âge, la séropositivité chez le 
donneur, la séronégativité chez le receveur, et une charge virale élevée 
pendant le premier épisode infectieux. Elle représente une infection 
prolongée plutôt que des épisodes séparés de virémie. 
Le taux de Df\IA de CM V dans le plasma à la fin du traitement est le 
meilleur facteur pronostic d'une infection prolongée. Chez les greffés avec 
un risque élevé de développer une infection prolongée, un traitement 
prophylactique s'avère particulièrement bénéfique et intéressant du point 
de vue du coût, puisqu'il évite des traitements multiples. 
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Background. Recurrent infection freql,letlttffbllqws !hl9Ja,JJ'ukoc~tes and plasma throughout a protracted 
the response to the initial treatment of cytomegalovi- (2::1 ll'lon~h) period including after preemptive or ther-
rus (CMV) infection in soÜd~Q'rg~!l, ti:ansplant (~O,T) apeutfo .ganciclovir courses. Predictors of protracted 
recipients. The objective of tl~i~::s1juµy lw~s .til, qéS,cfib1:1 ,:high-l~~.~i ih~ec#~ni werE:l 'il;wreasing age, CMV donor 
the course of CMV infection fo SOT pàtients' ànd to stfropositivith· aU:a all :ôieasures of viral load during 
identify factors that would predict protracted CMV the initial episode. CMV recipient seropositivity pro-
infection with recurrences. tected strongly against protracted infection. End of 
Methods. Quantitative polymerase chain reaction treatment plasma CMV DNA best discriminated be-
(PCR) assay for CMV DNA in leukocytes and in plasma tween patients who did or did not develop protracted 
were used to assess viral load chang~s.r\'lt1;'QSP~~~iy~ly t~fectfom U •.·~ , .•. . . 
in consecutive SOT patients, whos~ GMVinf~ctiQnep, i. Cdnplusî01'i8,,1In SQT patients, protracted CMV infec-
isodes had been attended therapeutically or preemp- tion is asso.ciated with increasing age, donor seropos-
tively using quantitative blood culture. i': 1, r.•J<, fit~f~fYi y~ci:I!ient s~ronegativity, and high viral load 
Results. Among 101 SOT patients, CMV irifectiOn· od~ durmg the first ep1sode. End of therapy plasma CMV 
curred in 63, of whom 32 developed recurrent infec- DNA level best predicts the occurrence of protracted 
tion after the initial episode. In patients with recm·- infection. In patients with a high risk of protracted 
rent infection, PCR indicated that a majority (27) of infection, prophylaxis is likely to be particularly cost 
recipients had high level of CMV DNA in peripheral effective. 
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Cytomegalovirus (CMV) remains a leading cause for infec-
tious morbidity in solid-organ transplant (SOT) patients (1-
6). Numerous approaches, using vaccines, immunoglobulins, 
acyclovir, and ganciclovir, have been proposed to limit the 
morbidity caused by CMV in SOT recipients (6-12). Cur-
rently, the optimal preventive approach for the prevention of 
CMV disease in the various solid-organ transplant recipient 
remains to be determined (13, 14). The efficacy ofprophylac-
tic oral ganciclovir has been demonstrated for liver (9), kid-
ney (15), and heart (16) transplant patients, whereas vala-
cyclovir prophylaxis seemed a safe and effective way to 
prevent CMV disease after renal transplantation (17). This 
approach seems to offer the added bonus of reducing the 
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incidence of acute rejection in high-risk, seropositive donor- per day for the first 2 days ~nd then orally at 5 mg/kg four times per 
seronegative recipient (D+/R-) patients (17, 18). In contrast, day. After 1997, only Sand1mmune Neoral was given at the same 
the rationale of preemptive approaches has been to concen- dose. CsA oral doses were adjusted to a predefined trough level in 
trate the use ofintravenous ganciclovir in patients at highest whole blood. CsA blood levels were measured by enzyme-multiplied 
risk of developing CMV disease. It has proved e:fficacious in immunoassay technique (EMIT, Behring, Marburg, Germany) using 
liver (12), kidney (19), and lung and heart transplants (20). a Cabas Mira+ machine (Roche, Basel, Switzerland). In high-risk 
To the best of our knowledge, the prophylactic and preemp- patients, azathioprine was added (2 mg/kg/day). Patients receiving a 
h second renal transplant or having acute rejection episodes were 
tive approac es have not been compared in a prospective given mycophenolate mofetil (l6 patients). 
randomized study. The potential for CMV infection to recur Cardiac transplant recipients underwent an antilymphocyte anti-
after (or persist despite) ganciclovir treatment of CMV dis- body induction regimen (ATGAM or ATG of 10 mg/kg/day) during 5 
ease has been recognized in as many as 12% to 59% of the days and received 1 g N of methylprednisolone perioperatively fol-
patients, depending on the type of organ transplant (21). lowed by 375 mg four times per day for 4 days. Subsequently, 1 
Identified predictors of recurrence have been primary CMV mg/kg ofprednisone was administered orally four times per day and 
infection (22-24), antirejection therapy and type of trans- tapered gradually; and 4 mg/kg of CsA, administered orally four 
planted organ (probably reflecting higher levels of immuno- times per day, and 2 mg/kg of azathioprine, administered orally four 
suppression) (25, 26), the severity of the initial episode (22), times per day, were given as soon as the patient was able to take 
and more recently, a higher viral load during the initial them. One patient had azathioprine replaced by mycophenolate 
episode (23, 24). Recurrent CMV infection has also been mofetil. Doses oforal CsA were adjusted according to trough levels in 
whole blood (approximately 150-250 ng/mL). 
described in 4114 (29%) kidney-transplant patients treated Hepatic transplant recipients received 300 mg of methylpred-
preemptively with ganciclovir for 3 weeks (19), raising the,, f ;nisolone Non the operative day. On the ensuing days, they received 
question as to what are the predictors of recurrent infecttmi.,, ;Ir;te~hylprednisolone (or prednisone orally as soon as they were able 
after preemptive treatment and whether recurrent infE)cüio;Ô/i ft?.;t,~kE) it) in doses diminishing by 40-mg steps, until they reached a 
should be treated preemptively (27). . 1 , , , ! l~~fl'.Y ~os.~of 20 mg. One to two mg/kg of CsA were administered IV 
For several years, we have be en managing SOT:pàt~en~s · · /~~r~~qiep per day, then orally at three times the daily N dose, with 
with CMV infection according to a preemptive°'gÈl;nçfofovir 1 a.~~f,j~tJ,)lopd level between 150 and _300 ng/mL. Azathioprine was 
approach using a quantitative shell vial assay for the'.détêc- admm~17:r:~d J:Y at 1 _to 2 mg/kg four tni;es per day, and then orally. 
tl.on of CMV Vl·rem·a •t · t l (28) R \t.l , ... ··. :1· 1,,A.cute reJect1on ep1sodes were operat10nally defined for the pur-1 as a mon1 onng oo . ecen y,. we, " · , · . . b d · . . 
· d · d t f t CMV . ·:1,:.·;•.•1: 'Pù$e.ofth1sstudy y the a mm1strat10noftreatmentagainstrejec-
expenence an mcrease ra e o recurren Vlremia ····t· ' ' ' · d · d ·1 1 · · 
. . . . ·. , , ,' ,1on ep1so es (i.e., >3 ai y pu ses ofmethylpredmsolone or antilym-episo~es ar:er preemptive treatment of CMV mfect10n. ·: , ::, plÎocyte therapy administered independently from the induction 
This article descnbes the incidence of protracted CMV ···· regimen), which were diagnosed by the usual clinical or histological 
infection with recurrences in a population of 10~ c.011sraçl1tive , criteria. 
SOT recipients, including using peripherali:bloqclil~(ikbcyte, jj · '" '( 
and plasma quantitative PCR for CMV DN'A.IWe denfon- · · ., Definitions 
strate that recurrent infection inçleed :i;e:f1yct~ a. pi;ptrlj.ctE)d Cyt9m,e1plpvirus infection and .disease were defined according to 
CMV infection that is not resoly~~ ,8.t it~e end('ofl'J?r~~~ptivè ~~tabli'E\h~d ,6qt~ria:: ~29){ 4.lal,Joratory diagnosis of CMV infection 
treatment. We also analyze poté:nliall.'riiskLfa:dt6rsi.,thât inay ',yl~a defipe~ by ~osttiv~. ~h~lh1i,atculture of any biological sample. 
help identify patients at risk for protracted infection after the Viremia was defined as positive culture from blood leukocytes. In the 
initial infection episode. absence of signs and symptoms (see below), this was considered 
MATERIAL AND METHODS 
asymptomatic infection. CMV infection with symptoms or signs at-
tributable to CMV (symptomatic infection) was considered CMV 
disease. 
Patient Populatiq~}· I if i.: 1 frti~.l1~1,1P~ivel.C~I\''~.~~y!).Se w~s defrr,ied as one or more of the 
Al! adult patients who underwent a hea~t, li~er, or trans- ·· followrng ·symptoms assocrated w1th positive CMV shell vial culture 
plantation at the Centre Hospitalier Universitaire Vaüdôis.·between (usu~µy ~iren,:iia): presumptive CMV syndrome: fever higher than 
January 97 and December 98 were considered for inbl~~ib'n\bf'.'this 3~~?0 \'.l iuid:,l~sting at least 2 days, or leukopenia ( <4000/µ,L), or 
retrospective study. thrombocytopenia ( <100 G/L), or all three symptoms. Presumptive 
Transplant recipients who died perioperatively or did not have a CMV organ disease was diagnosed as follows: (a) pneumonia: clinical 
minimal follow-up of at least 3 months for reasons other than death, symptoms with radiographie changes or hypoxemia; (b) hepatitis: 
namely Ioss of follow-up or primary graft failure with discontinua- serum transaminase disturbances (more than twice the previous 
tion of immunosuppressive drugs, were excluded from this study. value) or jaundice without other causes of hepatitis, or both; (c} 
Immunosuppressive Regimens 
Recipients of renal transplants received various induction regi-
mens. Five patients did not receive any antilymphocyte antibody 
induction. Fifty-two patients received antilymphocyte antibody in-
duction (ATGAM, Pharmacia & Upjohn, Peapack, NJ, n=22; ATG-
Fresenius, Fresenius Medical Care, Homburg, Germany, n=17; Or-
thoclone OKT3, Janssen-Cilag (Baar, Switzerland), n=2; 
Thymoglobuline, Imtix-Sangstat, (Lyon, France), n=5; or Simulect, 
Novartis Pharma, Basel, Switzerland, n=6). Induction included in-
travenously (N) administered methylprednisolone, 500 mg, on the 
first day, which was tapered gradually within the first 4 days post-
operatively. Since 1997, cyclosporine (CsA, Sandimmune, Novartis, 
Base!, Switzerland) has been administered N at 3 mg/kg four times 
gastrointestinal disease: gastrointestinal symptoms with diarrhea or 
bleeding, or both; and (d) neurologie disease: neurologie symptoms 
with encephalitis, transverse myelitis, or other central nervous sys-
tem symptoms, together with CMV detected in the cerebrospinal 
fluid. 
Proven CMV disease was defined as above but required a histo-
logical confirmation for hepatitis, gastrointestinal disease, and neu-
rological disease. Pneumonia in transplant patients could be based 
on 'evidence ofpneumonia with Cl\1V detected in the bronchoalveolar 
lavage or lung biopsy, whereas retinitis with typical ophthalmologic 
lesions was accepted without virological proof. 
Initial CMV infection was defined as the first CMV infection 
episode documented after transplantation. Recurrent CM:V infection, 
symptomatic or not, was defined as the reappearance of a positive 
blood leukocyte shell via! culture after an initial CMV infection 
•
.. J 
1 ' 
• 
• 
228 TRANSPLANTATION Vol. 74, No. 2 
episode, separated by at least one negative blood culture, whether 
induced by anti-CMV treatment or not. Intermittently positive vire-
mia with less than 3 IU/106 peripheral blood leukocytes (PBL) were 
not considered separate, recurrent episodes. Protracted CMV infec-
tion was defined as infection with a high viral load (> 10 ru by 
quantitative culture or > 105 copies of CMV DNA by real-time PCR 
per million PBL) observed in at least two separate samples at least 
1 month apart. 
Treatment administered to a patient was referred to as preemptive 
if it was administered because of recognized CMV disease risk fac-
tors in the absence of symptoms, and therapeutic if it was adminis-
tered because of symptomatic disease. 
DNA was extracted from PBL samples using the QiaAmp blood kit 
(Qiagen, Base!, CH) and amplified by real-time PCR using primers 
and probes for the target sequence of the HCMV UL 86 gene coding 
for the major capsid protein (31). To control for the efficiency of the 
extraction procedure, a real-time PCR system was set up for human 
{3-globin. TaqMan Universal Master Mix was purchased from Per-
kin-Elmer (Rotkreuz, Switzerland). Primers and probes were from 
Microsynth (Balgach, Switzerland). 
Amplification and detection were performed with an ABI 5700 
system (Perkin-Elmer). Beta-globin and CMV PCR were performed 
in separate reaction mixtures in duplicates. For each specimen, 
inhibition controls were run in duplicate by spiking 1000 copies of a 
linearized plasmid carrying CMV UL 86 ORF, encoding for the major 
Virological Monitoring capsid protein (CMV EcoRI D fragment in pACYC184, kindly pro-
The CMV antibody status of donors and recipients was determined vided by Dr. Deborah Spector, UCSD, San Diego) in the sample 
by enzyme-liuked fluorescent assay for anti-CMV IgG (Vidas, bi- extract. Calculation of cell equivalent and CMV DNA copy numbers 
oMérieux, Marcy !'Etoile, France). For the monitoring of CMV infec- in extracts was based on standard lines of 10-fold dilution series of 
tion, according to guidelines for the management of CMV infection human DNA extracted from HeLa cells and of pACYC containing the 
that were proposed during the time of the study, clinicians were EcoRI D fragment (that encompasses UL86) in carrier DNA in du-
asked to submit blood specimens for CMV shell via! cultures weekly plicates. Results were expressed as CMV DNA copy number per 106 
for the first 6 weeks after transplant and once every two weeks for PBL. Details concerning the primers, probes, and amplification pro-
the next 6 weeks. Weekly cultures for 4 weeks and biweekly cultures : f çedures, as well as their analytical performance can be obtained from 
for an extra 4 weeks were proposed after the treatment of an acµ:te ·.' ):t;ll,t).,.corresponding author upon request. 
rejection episode. Obtaining cultures for 1 month was also pro:Pbs~d 1 Io:.: Qitantitative competitive PCR: Amplicor CMV monitor assay. 
after a CMV viremia episode, independent of treatment and.::tiüfo .' lt:ll.~,com,mercial method was used to measure CMV DNA load in 
after transplantation. Samples taken at the time ofpeakyiVilJl~~d.:,o.t\ 1"pJllsffi:a s~n:iples. The manufacturer's instructions were followed for 
an untreated episode or within 48 hr of initiation of antiviral'treat~ , ; a}l s#a!S~# of: :the process, including sample preparation, amplifica-
ment were called peak samples. Samples taken within 48 Ii'bipfthe tion; an<l détection. Contamination was prevented by the inclusion of 
termination of a treatment were called end-of-treatment samP,!ti~:. 
11
, }.mperllse' (uracyl-N-glycosydase) in the master mix and by substi-
Blood was harvested in 8-mL EDTA-Monovettes tubes (Sa1'stedti: . tüthÎg dUTP for dTTP. 
Sevelen, Switzerland) and processed within 2 hr in the Diagnoètic 
Virology Laboratory for CMV shell vial assay. PBL prepared by'.; Statistical Analysis 
hypotonie lysis of red blood cells were used in a quantitative shell , Demographic, clinical, and microbiological data were collected. 
via! assay using in house human embryonic lu,ng !fibrobliJ.st~ as , Eor.the 1comparison between patients with and without CMV recur-
recently described (28, 30). Aliquots of plasma and PBL:wé~I) frôzJii, ,li ,j-ent ~pis~des, ouiiy data within the first 3 months (i.e., the period of 
at -80°C until extracted for PCR. ' 1· '• ·· ·• ·· ·I the plànn'edlvirolbgical surveillance) were included. For this compar-
Preemptive Treatm.ent (h)iqeli,l,,es , . /; h; .y · 
', .. \'1· .'' :.'.: !1,: :· ·"'_,;·. l!'i, ',} '..' ' 
Treatment with ganciclovir (2xs\X:~!kg/day br ad~pfed tÔ r~nal 
function) for 15 days was proposed for al! symptomatic patients and 
for patients with asymptomatic viremia and the following risk fac-
tors for CMV disease: (1) D+/R- serostatus; (2) treatment rejection 
within the previous 2 months; and (3) viremia higher than 10 posi-
tive nuclei/106 leukocytes. This eut-off value was used because.it was 
shown recently that levels of viremia ~bo\ÎciÜt.'iJ.f.eiédai<lW~e'df 
inlpending CMV disease (28). The treatment had t~ b~ iniÙ~t~1d nô 
longer than 24 hr after diagnosis of symptomatic CMV'idis,ease ol.'172 
hr after the indication to treatment of asymptomatic è:JMV irl.fe6tioli 
was recognized. In case of ganciclovir toxicity, foscarnet (60 mg/kg 
N, three times per day) was proposed. No antiviral prophylaxis was 
used in these patients. 
Compliance to Pe1forming Surveillance Cultures 
Compliance was defined as the percentage of shell via! cultures 
made in accordance with the prescribed microbiological monitoring 
guidelines (e.g., 9/9 cultures=l00%). For a culture to be counted as 
performed, it had to be performecl within 2 days of the prescribed 
date. If more than 1 culture per week was performed, only one per 
week was counted to determhie compliance. 
Retrospective Analysis of CMV DNA Load in PEL and in 
Plasma Samples 
Quantitative real-time PCR. PBL and plasma specimens from 
transplant patients during and after viremic episodes were retro-
spectively analyzed for CMV DNA. The laboratory personnel per-
forming the PCRs was blinded to the clinical and quantitative cul-
ture data. 
ison, t):ie,p,atient who died during an initial CMV episode was also 
~:X:cludéd::1befàuse h'e did!not have the opportunity to develop recur-
11·~rlt infêdtion..I: L .,.· f '·.; .· L J \:) '·· >· 
Data of patients with and without recurrent or protracted infec-
tion (see these definitions) were tabulated and compared by Fisher's 
exact test for categorical variables and by Wilcoxon rank sum test for 
continuously distributed variables. Al! tests were two-sided. The 
following possiJ:ile risk factors for recurrence were analyzed: demo-
il}·~IJ,ic qa~1~, fyii~'. cjf ,orgip1 transplant, donor and recipient CMV 
èei·osfatu~, imrriuribsupp1~essive agents used (both for induction and 
.treiJ.fa11ent o{ ,acute rejection), type of treatment of hlitial episode 
':ctMrapep,tië. !or preemptive), acute rejection, and viral load 
d~t~rminati~~{s. 
These data were also analyzed by logistic regression analysis to 
examine the odds ratios associated with these variables. After iden-
tifying variables influencing significantly the risk of protracted in-
fection by univariate analysis, age, donor, and recipient CMV 
serostatus, viral load were entered into a stepwise multivariate 
logistic analysis. Computations were performed using the Stata soft-
ware (Stata Corporation, College Station, TE) . 
RESULTS 
Demographic Characteristics of the Patients 
From 1997 to 1998, 111 patients underwent solid-organ 
transplant in our hospital. Four patients died during the 
perioperative period and are excluded from this study. Two 
patients returned to dialysis and had immunosuppression 
discontinued 22 and 25 days after transplantation because of 
acute vascular rejection requiring graft explantation and cy-
closporine-induced microangiopathy respectively. Four pa-
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tients were lost to follow-up during the 3-month period of 
surveillance according to the preemptive approach guide-
lines. The remaining 101 patients are the subject of this 
study. One patient had a simultaneous heart and kidney 
transplant and has been included arbitrarily in the kidney 
transplant category. Table 1 demonstrates the demographic 
characteristics, including the risk factors for developing CMV 
infection and disease. A majority of the patients (56%) un-
derwent kidney transplantation. Patients had a variable pro-
portion (from 2/9 to 9/9) of their surveillance cultures per-
formed. Overall, however, a large proportion of surveillance 
cultures were indeed performed (85±22%). Only one kidney-
transplant patient had preemptive IV ganciclovir adminis-
tered while he was receiving OKT3 antibody treatment for 
acute rejection. 
multiple episodes of CMV viremia with proven CMV 
hepatitis. 
The proportion of recurrent episodes during this 1997 to 
1998 period was dramatically increased (54%) over the pre-
vious 2-yr period (1995-1996) when it was 25% (28). When 
risk factors for CMV disease were compared between these 
two study periods, the only significant CMV risk factor 
change to explain this fact was an increased proportion of 
D+/R- high risk patients from 15% to 26%. 
Performance of Real-time Quantitative PCR 
During this study period, the surveillance for CMV in-
fection was based on a quantitative culture assay. To test 
whether the quantitative detection of CMV DNA could 
provide more information than culture, samples of periph-
Incidence of CMV Infection and Disease eral blood leukocytes were saved and retrospectively ana-
Table 2 demonstrates the incidence and characteristics of lyzed by a newly developed real-time quantitative PCR. 
CMV infection. Overall, 63 (62%) patients developed CMV Experiments using plasmidic target DNA diluted in hu-
. fie ti'on fi t t 1 f 140 . d CMV. fi t' d , .. man DNA, or DNA extracted from CMV-infected fibro-m c , or a o a o ep1so es. m ec 10n cause ,. ;1 :·:bl ( ) . d' d h h 7 • ym ton1s · 39"' f th 63 · 't' 1 · d 1 · t ..•. •, , asts 30 , m icate t at t e assay has a 1 to 10 copies s p 111 10 o e 1111 la ep1so es. none ms an,cg, >11d···· . , . h 1 1 . CMV arguabl t "b t' f d tl . k' d"' ·; • > 'i i ·. yp,am1c 1 ange w1t cyc et 1resholds varymg from 38 to 15, 
Y .was a con .11 u mg cause 0 ea 1· ~ }}t.eY1 :1 ! p:fo'p' 'cmtionally to the Log of the inp t CMV 1 · d 
transplant patient expenenced acute vascular re3ection 3.;,, f •/ · >, . u P asmi copy 
l ft . . /.\' ,,,,: '' '• ;numher·with a r
2
=0.998. Repeated measures on samples wee Œ a er transplantat10n and was treated w1th a ,COl:[rse:bf \. , ~' : , , 
OKT3 antl'b d o 1 1 t h d 1 d C"..,·.·.,,·:.; ·.·.·:...·.··•.'·.':....·.· .. :·".·.···· ·, •conta .. ;in[p.·.g.·from 236 to 28,500 copies ofCMVDNArevealed o y. neweet aer, e eveope ivi.:v:;:vi:+euna, · .. · .. • .. /• .. •':.'.' . . . 
h . h as t t d 'th · 1 · H th 1·.::.' ·• ,~. ·,•• ··1· that ,, the· .coefficient of vanat10n of the assay averaged w 1c w . rea e :iv1 ganc1c. ovir. e never e es~,~uev8,,.~, ,, 55 :+:J:So/o SD . 
oped mult10rgan failure and died 11 days after ganc1qlo:v1r : ?' ·' ., ( ) . . . . 
· 't' t' Th t t l d d' · t d B""'''' 1·1• .. , ,: ~ ... 1·The CMV DNA content 111 395 chmcal specnnens (1-20 1111 la 10n. e pos mor em revea e a 1ssem1na e ~ce ·::·::,,:,,·,· •.". . . 
lymphoma and CMV pneumonitis. · .. :;';:.~;pec1men p~r patient) ~f penpheral blood leuko?ytes of the 
More th n h lf ( 76 54"') f th · d t d 1 : present patient populat10n was therefore determmed. In ad-a a n = , ·10 o e ep1so es represen e , . . 
· f . . ,1 • • dit10n, plasma samples were analyzed for CMV DNA by mstances o recurrent 111fect10n. In fact, 32 1patier1ts 1ex;per1- C·"b , 'A-'-'''l'''····.· CMV M 't 1 ,, · d t · fi t' 'th 20 . t 111 1· 11 . ;·," m' : , , · o as .t~rn:p 1èor 0111 or assay. n iact, of 63 patients ence recurren mec 10n w1 patien s experie~:icuw . ore, · 'tHC:MV'' fi St' 34 h d PBL d 32 h d 1 1 than 1 recurrence (up to 8 recur.re. nt episodès'),fot a foedia'n W~ .. ;
1
' .b .. 
1 
.. fi1~n eh. rnn, 
1 
.a an a P asma samp es 
b f . avai a e or t 1s ana ys1s. num er o 2 recurrences anc]\a.:meàn of2.24 ep1sode per · · · · ,· , 
patient. The proportion of sym°ptbniktid infec~iofl:,: whs l6we~ ;, !:(/ : !, (/ .L i! , ., \ 
in recurrent infection, but neverthèles~ ~bdut b1{~--fi:ftlî\:fa%) Coit/'ïje of CMJ!Vira,i Ë9çzd··in Selected Patients with 
of these episodes were symptomatic. In addition, another CMV Infection 
21% of these episodes were of such a viral load level that Figure 1 shows examples of the evolution of the viral load, 
preemptive treatment was prescribed according to the guide- as measured by quantitative rapid culture and by quantita-
lines in the same manner as for initial episodes. Among tive CMV DNA assay in the leukocytes (real-time PCR) and 
cli~ically signi.ficant recu~rent CMVi·:epj~o~~s\;,1 Yfr ~ ?~~~P\f:lg i~ Bl;;t~~a ;(Coh'a~,~~Upor CMV Monitor) in several patients 
for mstance a hfe-threatenmg CMV pnémnànlà'dührtga 'first wliàprèsèr\.teddîffèrent patterns of CMV infection. Figure la 
recurrence (second CMV episode) 2 months afte11):iea:rttra:r:s7 .qepipts th(c] ,:evolution of a patient with primary infection 
plant, a thrombotic thrombocytopenic purpura db'rllig 3, higl):~ 11;fD tm+f s~rl:>status) presenting with recurrent viremia de-
level first recurrence (second CMV episode) 2 months after spi te three treatment courses. The last viremia episode, char-
liver transplant, and an accelerated course of recurrent hep- acterized by an especially high lev el of CMV load lasting for 
atitis C toward cirrhosis in a liver transplant experiencing several weeks, starting more than 3 months after transplan-
TABLE 1. Baseline characteristics of patients and incidence of CMV and other opportunistic infections 
Characteristic Organ Total 
Organ transplanted He art Kidney Li ver 
Number of patients (n) 19 57 25 101 
Age (yr, mean±SD) 56.2±5.7 48.3±11.4 48.9±9.8 49.9±10.5 
Gender (M/F, no) 18/1 40/17 19/6 77/24 
CMV serostatus pattern (n, %) 
D-!R- 4(21%) 9 (16%) 6 (24%) 19 (19%) 
D-IR+ 4(21%) 14 (25%) 4 (16%) 22 (22%) 
D+/R- 7(37%) 12 (21%) 7 (28%) 26 (26%) 
D+/R+ 4(21%) 22 (39%) 8 (32%) 34 (34%) 
Acute rejection (n, %) 12 (63%) 31 (54%) 6 (24%) 49 (49%) 
% of planned surveillance cultures performed 83±19% 94±11% 66±28% 85±22% 
• 
.. 
1 
! 
.. , 
• J ' 
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TABLE 2. Incidence and characteristics of CMV infection 
CMV infection (n, %) 
Recurrent infection (n, % of CMV-infected) 
Protracted infection (n, % of CMV-infected) 
Total infection episodes (n) 
Type of initial episode 
Total (n, %r 
Asymptomatic, untreated (n, %)b 
Asymptomatic, treated preemptively (n, %)b 
Symptomatic, despite preemptive treatment (n, o/o)b 
Symptomatic, treated (n, %)b 
Type of recutTent episodes 
Total (n, % )a 
Asymptomatic, untreated (n, %}° 
Asymptomatic, treated preemptively (n, %)c 
Symptomatic, despite preemptive treatment (n, %)c 
Symptomatic, treated (n, %)c 
Mortality due to CMV 
Opportunistic infectionsd 
He art 
10/19 (53%) 
4110 (40%) 
3/10 (30%) 
18/140 
10/18 (56%) 
3 (30%) 
4(40%) 
0(0%) 
3 (30%) 
8/18 (44%) 
3 (38%) 
3 (38%) 
0 
2 (25%) 
1 
5 
a% of all, initial and recurrent, episodes. ·i 1,:, 
b % of initial episo~es for each transplant category. , :: 
1 
::,:[ \ ::',: 
Kidney 
40/57 (70%) 
20/40 (50%) 
16/40 (40%) 
93/140 
40/93 (43%) 
14 (35%) 
9 (23%) 
1(2%) 
16 (40%) 
52/93 (56%) 
33 (63%) 
12 (23%) 
0 
7 (13%) 
1 
1 
Vol. 74, No. 2 
Llver Total 
13/25 (52%) 63/101 (62%) 
8/13 (62%) 32/63 (51%) 
8/13 (62%) 27/63 (43%) 
29/140 140 
13/29 (45%) 63 (46%) 
4 (31%) 21 (33%) 
3 (23%) 15 (23%) 
1(8%) 2(3%) 
5(38%) 25 (39%) 
16/29 (55%) 76 (54%) 
8 (50%) 44 (58%) 
1(6%) 16 (21%) 
0 0 
7 (44%) 16 (21%) 
0 0 
2 8 
c % of recurrent ep1sodes for each transplant category. . ....... : ;''! :, :li 
d Among heart transplant patients: toxoplasmosis (2), tub'rircµIosiki(l)/P. carinii pneumonia (1), and Nocardia pneumonia (1); kidney 
transplant patients: P. carinii pneumonia (1); liver tran~pfa'Q~P<i;~i~nt'~ij,ëgûJn'.nelfo pneumonia (1), visceral Leishmaniosis (1). 
/·.,·~~~:.:_1:!:~!( '', '•<_ ~ !' !:· ·' .r( ' (i:1,, 
'···. __ -_,,.J':::." 
''~:,·.·: ·. 
tation, was accordingly not treated preemptively but ,,âh :, tirog 9f'initial infection, but also in the profile of viral load 
tended with watchful waiting. The only symptom ~aW'a;:,:' chariges over time after initial infection. Because some of the 
marked fatigue accompanied by thrombocytopenia, whicl\:1.! patients presented with low viral load recurrences of little 
both resolved simultaneously with a precipitous viral load '; clinical significance, we attempted to replace the culture-
drop in the absence of antiviral treatment. Of note,, a similar . d,erived .cpncept of "recurrent infection," i.e., viremia episodes 
; , li• ~.' , i l 1 ~ • ~ i (: ' ' , T <. ' ," "•; 1, é_'. ' \j ' 
pattern of spontaneous eventual resolution of c~ mfect3op;.,, :1 1~epa;Tated PY a pegative culture. Acknow ledging the fact that 
as defined by no recurrent CMV disease or virémia aftèr' a , • CMV·ïnfection was not resolved in these patients as indicated 
last episode ofhigh-level viremimwith a leukocyte CMV DNA by PCR.data at the end ofpreemptive treatment (Fig. lA and 
load in the 106 to 101 range, J~116,+e~ by a spoq~an~o~~ ,'.13), we:iri69Çpo~at~~ btjti~ ~ ~r~l load and a duration criteria 
precipitous decline of CMV load'i~{ tb'elbldod (Figi lA; f'rbn-i 1i11the 11ew d~flhition of'1proti'acted high-level infection," (i.e., 
day 105-135 after transplantation) was observed in nine the observation, at least 1 month apart, of a viral load >10 
patients (seven with the D+/R- serostatus pattern and two CMV IU or> 105 copies of CMV DNA/106 PBL). As indicated 
with the D+/R+ pattern). by Table 2, the somewhat more stringent definition of pro-
In fact, CMV DNA was continuously detectable in the tracted infection led to the reclassification of five patients 
leukocytes and plasma of this patiezj:t,::ri'l:ngi11g,fi:or)1:[~Q 5, tg wit~1pic~en,'t i):i~ecti~ll as not having protracted high-level 
106 copies/106 leukocytes and from' 104' tb' 1Q'i cdpièé/mL infectfori 1(saniple 'patiei1ts depicted in Fig. lC and D). The 
plasma throughout the three initial viremic ~~fa~d,estJ:i~t • cl)l~~~tio:.i of, 1protracted high-level infection varied substan-
were treated and reaching close to 108 copies and ::?;1Q~·cbp~ ~fall:Y<\.Vith,\li median time from first to last high virus load 
ies, respectively, in PBL and plasma during the last high- sample of 73 days (range: 30-227). 
level viremia, in the absence of treatment. 
Figure lB depicts the course of D+/R- heart transplant 
patient with a CMV infection course similar to the previous 
one. Figure lC depicts the course of a D+/R+ kidney-trans-
plant patient who presented a clinically nonsignificant CMV 
recurrent infection after preemptive treatment of an initial 
episode. Figure lD depicts the course of a D+/R+ kidney-
transplant patient who presented with spontaneous recur-
rent episodes of viremia that did not require preemptive 
treatment according to our guidelines. Figure lE and F 
present the infection course of a D-/R+ heart-transplant 
patient and a D+/R+ kidney-transplant patient who pre-
sented without any recurrence after an initial infection epi-
sode treated preemptively or not. 
Together, these detailed longitudinal descriptions of the 
course of CMV infection in the wake of transplantation indi-
cate a wide variability not only in the peak viral load at the 
Risk Factors for Protracted Infection 
It would be of major interest to identify early predictors of 
protracted high-level infection to adjust the management of 
CMV infection to this risk. To identify risk factors for pro-
tracted CMV infection, patients with CMV infection were 
classified according to whether they developed (n=27) or not 
(n=36) protracted infection and compared with respect with 
a host of clinical and microbiological potential risk factors. 
For this analysis, only events occurring within the 3-month 
period ofplanned surveillance were taken into account. Table 
3 demonstrates that patients with protracted infection were 
significantly older than patients with nonprotracted infec-
tion. The risk of protracted infection did not significantly 
differ across the different types of organ transplant. The 
donor/recipient serostatus pattern was also a very strong 
predictor for protracted infection, which rose from 0% to 95% 
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::::~~ 1. Course ~f C~ infect~on in six patients (A-F) after SOT. DIR, donor-recipient CMV serostatus. PBL infectivit as 
ured by quantitative shell vial assay (blue triangles arithmetic scale onleft y ax' ) d CMVDNA (PBLb l · y 
· d · · 1 d 1 b c b · ' is an Y rea -time PCR, 1thre eue es, an P a~ma Y ~ as Amphcor CMV Monitor, black inverted triangles, logarithmic scale on right y axis) are sh 
oughout the per10d of active follow-up of the t' t 0 t 1 . , own , . . pa ien s. pen rec ang es, ganc1clov1r treatment; asx, asymptomatic episod 
sx, symptomatic ep1sodes. *Out of range values ( <400 or > 105 copies/mL)o es, 
across the different patterns (P<0.001, Fisher's exact test). 
Whe1~ serostatus pattern groups were cornpared pairwise, 
the nsk for protracted infection was significantly higher in 
D+/R- patients compared with D+/R+ patients (P<0.001) 
but not in D+/R+ cornpared with D-/R+ patients (P=0.12). 
Protracted infection was not significantly associated with 
any peculiar immunosuppressive drug used in the induction 
or maintenance of inmmnosuppression, or with acute rejec-
tion or its treatment. 
Viral Load During the Initial Episode as a Risk Factor for 
Subsequent Protracted Infection 
The relationship between viral load measures during the 
initial viremia episode and the development of protracted 
231 232 TRANSPLANTATION Vol. 74, No. 2 
TABLE 3. Distribution of potential risk factors among patients with and without protracted CMV infection 
Type of CMV infection risk factor Nonprotracted (n=36) 
Age a 48.5 (25-68) 
Organe 
Heart (n=lü) 7/10 (70%) 
Kidney (n=40) 24/40 (60%) 
Liver (n=13) 5/13 (38%) 
CMV serostatus patternc 
D-/R- (n=l) 1/1 
D-/R+ (n=16) 15/16 (94%) 
D+/R+ (n=27) 19/27 (70%) 
D+/R- (n=19) 1/19 (5%) 
Tacrolimus 5/36 (14%) 
Anti-IL2R antibody 2/36 (6%) 
Azathioprine 13/36 (36%) 
Mycophenolate mofetil 8/36 (22%) 
Acute rejection 23/36 (64%) 
Pulse methylprednisolone (total grams)U 22/36 (61%) 
2.5 (0-6) 
OKT3 6/36,(;_ 7%) 
Protracted 
(n=27) 
56 (35-67) 
3/10 (30%) 
16/40 (40%) 
8/13 (62%) 
0/1 
1/16 (6%) 
8/27 (30%) 
18/19 (95%) 
4/27 (15%) 
1127 (4%) 
8/27 (30%) 
6/27 (22%) 
15/27 (46%) 
12/27 (44%) 
3 (1.5-6) 
4/27 (15%) 
Pvalué 
0.0185 
0.309 
P<0.001 
1.000 
1.000 
0.788 
1.000 
0.136 
0.212 
0.351 
0.944 
a Median (range). , ~ ,:: :: ; , > 
b Statistical comparisons were performed by Wilcoxon's rank s~lri t~l;lt fqr continuons variables and by Fisher's exact test for categorical 
variables. . ;' 1i:\)!:,,:({.;., . . . . ... 
c For organ transplant category, serostatus pattern, % mélicate,tl:J.e p~b:portym,of,patients with or without protracted mfect10n w1thm each 
category or pattern . 
infection was also analyzed. Figure 2 demonstrates tha,t~h #~yelbp protracted infection. Significant univariate predic-
measures of viral load during the initial viremia episode wer'e 'û>i'~ were exarnined in a stepwise multivariate regression 
significantly higher among patients who developed a pro:,' • ,model. The only viral load measure entered in this model was 
tracted infection compared with those who did not. However, the peak PBL infectivity, because data for this measure were 
there was a substantial overlap between the ~iraJ loa<;l,dataof .fl-vai}abl~ f9i:''aV patients, in contrast to PCR data. As can be 
the two groups regarding peak PEL infectivity, p,eilk' a,nd ,$1id 'see:n' from Tabl~ 4, in the multivariate model, recipient sero-
oftreatment PBL CMV DNA, and peak plasnrn CMV DNA, so positi~ity ~nd peak PBL infectivity remained significant in-
that none of these measures èbtilcf bE\, ased alon(l to. predict deperi~é'~'t,p11ecJ.ict9rs qf:ffotrncted infection. Age remained of 
whether the patient would experi~nce:aiprdtract~êl.i:ll:f13ètion, •, botderlâ.iie s~g'.nifica'.'1-ce,i, w:hercyas donor seropositivity was 
In contrast, end of treatment pl~srirn OMV DNA best dist!ti~ dropped from the'môdèl for lack of significance. 
guished between patients who developed or not a protracted 
infection (Fig. 2, lower right panel). In fact, by using a eut-off 
value of 2000 CMV DNA copies/mL plasma, this test had a DISCUSSION 
sensitivity of 100% and a specificity qf 89% for P~.e<;licting ,, Eecurr~:nt QMV,infection and disease are comrnon prob-
protracted infection. i 1 !, 1' , j 1' ', L ieilisl1fnl~oli~~Qrghi): ti'ansplant patients (21, 22, 24, 25) . 
Logistic Analysis of Risk Factors for Protracte,dJnfection Various risk factors for recurrent CMV disease and infec-
Finally, logistic regression was used to asses~· th~,q~ai~Ü~ fioh ·#~ve bê,en recognized in the se studies (see Introduc-tl~h)'. Ho'l\rever, to date, our study is the largest exarnining tative relationship between risk factors (including age, CMV 
donor and recipient serostatus, occurrence of acute rejection, both clinical deterrninants and molecular rneasures of viral 
imrnunosuppressive drugs used for induction, baseline im- load during the first episode as predictors for recurrent 
munosuppression and treatment of acute rejection, virus load infection. In addition, our patient population was charac-
during the first episode using the various assays, and mode of terized by a high rate of recurrent infection, in part be-
treatment of initial episode [preernptive or therapeutic]). Ta- cause of the fortuitously high proportion ofhigh-risk CD+/ 
ble 4 demonstrates patient characteristics that significantly R-) patients arnong our patients during the study period. 
predicted protracted infection by univariate analysis: per Thus, this study offers an unprecedented opportunity to 
decade of age, the odd of developing protracted infection analyze the determinants of recurrent CMV infection in 
increased nearly twofold. A CMV-seropositive donor con- solid-organ transplant patients. 
ferred an approximately 20-fold odds increase of developing During the study period, the patients were rnonitored 
protracted infection, whereas being a CMV-seropositive re- virologically using a quantitative shell vial culture (28), 
cipient diminished the odds close to 100-fold. Among the and stored blood samples were retrospectively analyzed for 
various measures of CMV viral load during the initial epi- CMV DNA in PBL and plasma fractions. Although blood 
sode, all predicted an increased .risk, with an odds ratio per culture turned quickly negative during ganciclovir treat-
Log increase varying from 2.79 for end of treatment CMV ment (Fig. lA and B), CMV DNA was frequently detected 
PBL DNA to 33.15 for end of treatment CMV plasma DNA, in the PBL and plasma fractions during, at the end, and 
which again appeared as the strongest predictor of the risk to, after ganciclovir treatment, in particular in patients who 
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FIGURE 2. Viral load during initial CMV infection episodes, analyzed by infection outcome. Peak value was defined as the 
value from the samples with the highest value during the infection episode, or when antiviral treatment was administered, 
the value of a sample taken within 48 hr of treatment. End of treatment value was defined as the value of a sample taken 
within 48 hr of treatment end. Individual values are shown, with the bar representing the median value. Values of patients 
with or without protracted infection were compared using the Wilcoxon rank sum test. 
later developed recurrent infections. This led us to inter-
pret recurrent infection in these instances as the expres-
sion of a protracted, unresolved infection, with antiviral 
treatment suppressing transiently CMV replication, which 
resumed after treatment was stopped .. This pattern appar-
ently continued until a spontaneous control of CMV vire-
mia occurred, which most probably reflected the develop-
ment of effective immune responses. 
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TABLE 4. Univariate and multivariate logistic analysis relating risk factors to the development of protracted infection 
Predictor OR (95% CI) P 
Univariate 
Age (per decade increase) 
D+ serostatus 
R+ serostatus 
Peak PBL infectivity (per Log increase) 
Peak PBL DNA (per Log increase) 
End PBL DNA (per Log increase) 
Peak plasma DNA (per Log increase) 
End plasma DNA (per Log increase) 
Multivariate (entering age, Da and R serostatus (excluding D-/R-) 
and start PBL infectivity) 
Age (per decade increase) 
R+ serostatus 
Start PBL infectivity (per Log increase) 
a D+ serostatus dropped for P=0.28, >0.1. 
1.90 (1.06-3.73) 
19.5 (2.37-160.3) 
0.014 (0.0017-0.125) 
12.48 (3.34-46.59) 
2.90 (1.02-8.20) 
2.79 (1.11-7.02) 
4.18 (1.25-13.99) 
33.15 (2.64-415.8) 
2.28 (0.91-5.69) 
0.031 (0.003-0.329) 
7.79 (1.75-34.57) 
0.03 
0.006 
<0.001 
<0.001 
0.045 
0.029 
0.02 
0.007 
0.076 
0.007 
0.004 
We also observed in several instances low-level recunent tian for the increased incidence of tuberculosis that is ob-
viremia, after or not ganciclovir treatment (Fig. 1, c and d)" ;1; served in elder patients in low tuberculosis-prevalence pop-
Because these remained asymptomatic in the absence of trefLt'; 1 i'u:lations (33) and for the increasing incidence of zoster with 
ment, we coined a more stringent definition ofrecurrentii;J,fec-' · l!lgél(34). To the best of our knowledge, our data for the first 
tian, which would incorporate bath a viral load critetjptt'(;?:j.q · :~i~I? C!l).antitatively document the age-dependent decreasing 
infections units or 105 CMV DNA copies per 106 J=>BJ'.,/ aD:d{a\ \è,a'Padt~ofthe immune system in SOT patients over middle 
duration criterion (two high viral load measuremerit~at!)eas~ l ' ':'lge:decade~to mount an anti-CMV immune response capable 
month apart). We coined the term ofprotracted (high vir~Hoad) ofi:ohta;iMng viral replication. 
infection to stress this duration component of the de:firµ#o:h~ \' 1 ThE) major predictor of protracted CMV infection was the 
Our preemptive approach has the potential to prevent th~a.P'; 1 •• cfon~r-recipient serostatus pattern with a significantly esca-
pearance of symptomatic CMV disease in the majority of cases. ,.·Iating risk from the low-risk D-/R+, to the intermediate 
(28), thus leading to an underestimate of the pathogenic poten- ' D+/R+, and to the high-risk D+/R- pattern (primary infec-
tial of CMV during initial and recunent infeë.tiort: As. a, G?f!S.~-
1 
tian) groµIl· /1'~1is shows that the risk for protracted CMV 
quence, we did not request symptoms to bë pi;es~riL iri P\11' ,J :fofe~tion, i:jaral~els the risk for CMV disease in transplant 
stringent definition of protracted infection.· ·1 ·· i ·· " ;,I • ·•. patients (4; 13)'. This finding is consistent with observations 
U sing the stringent definition,:we had in mind to ana- by oth.el(sJWho found tha.t CMVprimary infection (the D+/R-
lyze predictors of clinically sig11~tïdnt rècu~rep.c~<.Vl!itli .a . p~tterrâ aP:ci,t~e ~évefÏty,~f QMV disease during the initial 
high probability of disease or· bf fe1qulriiJgi pr~e~hp'tive 1'epfoodèi'~~e ptedicto11 .'fo~ récurrent CMV infection and dis-
treatment. In fact, among the 63 patients with CMV infec- ease (22-24). Logistic regression allowed to analyze sepa-
tion, only 27 (of the 32 patients with recurrent CMV vire- rately the influence of donor and recipient CMV serostatus 
mia) had protracted high-level infection according to this on the risk of developing protracted infection: whereas an 
stringent definition. Categorical statistical analyses for organ from a latently infected donor significantly increased 
risk factors for recurrent infection ('\Vere pe:vf~w1éd' i.ising 1 the odgs ofprbt~ac;:ted,iP;fection by univariate analysis, being 
ei ther de fini tian: carrela tians wi th ri~lt : f~ctot~ '\vllrè iurti ~ 1 & l~tè:rl'tiy iiife16t~d fodi~îent diminished strikingly this odd by 
formly more significant using the stringent1(.J?l:ptracted · ~b9ut,. 1QO-f91d! In fact, in the multivariate model, donor 
infection) compared with the plain (recurren:t ihÎéctiori') ~e1'1pP,q;3Î:tîVj.ty lost its significance, whereas recipient seropos-
definition. Other analyses (logistic regression) were per- itivity remained strongly protective. W e interpret these data 
formed using the stringent definition. as showing that the most important protective factor against 
When analyzing the effect of clinical predictors, we did not protracted infection is the existence of an anti-CMV immune 
find the type of organ transplant to affect significantly the response before the transplantation procedure. CMV-specific 
probability of protracted infection. Ali three types were cytotoxic T lymphocytes have been shown to control CMV 
therefore analyzed together. However, because of the rela- viral load and to prevent CMV disease in the first months 
tively small number of heart or li ver patients, one should be after renal transplantation (35). It is likely that the existence 
cautious before extrapolating our analysis to different trans- of a pool of CMV-specific memory T cells in seropositive 
plant categories. recipients enables them to generate a protective immunity 
Although the occurrence of CMV infection was not signifi- much faster than in seronegative, CMV-naïve recipients. 
cantly influenced by the patient age, patients with protracted This may in fact also be consistent with the observation that 
infection were aider than patients without: by logistic regres- a low level of activated CD8+ T cells in the blood of kidney 
sion, each decade nearly doubled the odds ofprotracted CMV and liver transplant patients at the end of the treatment of 
infection, a significant increase by univariate analysis that the first CMV episode is associated with a high risk ofrecur-
remained nearly significant by multivariate analysis. It has rent CMV disease (23) . 
been widely observed that, with aging, substantial changes CMV viral load, particularly in the blood, carries prognos-
occur in bath the functional and phenotypic profiles of T tic information regarding the risk ofimpending CMV disease 
lymphocytes (32). This is usually considered as the explana- (36, 37). By analogy, we wondered whether the viral load 
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during the first CMV infection episode would carry informa-
tion as to the risk of protracted infection. By all measures, 
the viral load was significantly greater in patients who went 
on to develop protracted infection compared with those who 
did not. This is similar to the data reported by Sia et al. (24), 
who determined pre- and posttreatment PBL and plasma 
CMV DNA load by competitive PCR in 24 SOT recipients, 8 
of whom went on to develop recurrent infection. However, 
there was a substantial overlap between the viral load data 
in patients with and without protracted infection in particu-
lar with respect to peak (pretreatment) viral load. In con-
trast, plasma CMV DNA at the end oftreatment seemed the 
only test with a diagnostic performance sufficient for use as 
a predictor for protracted infection. 
AU our patients had peak viremia data, whereas only a 
subset had samples available for retrospective PCR analysis. 
Therefore, peak quantitative viremia was the only viral load 
treatment. On average, primary prophylaxis may save up to 
2 to 3 preemptive and therapeutic courses in seronegative 
recipients, making it particularly cost effective compared 
with the preemptive approach in this subset of patients, with 
the added proven bonus ofpreventing acute rejection (17, 18). 
In contrast, in seropositive recipients, ofwhom only a minor-
ity will require usually a single preemptive course, the pre-
emptive approach is likely to be drug saving and cost 
effective. 
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Background. Graft-versus-host disease (GVHD) is 
still a major problem in allogeneic boue marrow trans-
plantation (BMT). Prophylactic regimens used against 
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GVHD in unrelated BMT, including cyclosporine 
(CsA)-plus-methotrexate (MTX), CsA-plus-MTX-plus-
prednisone, and tacrolimus (FK506)-plus-MTX, are 
still unsatisfactory (34-70% occurrence of grades II-IV 
GVHD). To address this problem, we examined the 
efficacy of FK506-plus-MTX-plus-methylprednisolone 
(mPSL) in 20 patients who underwent BMT from un-
related donors. 
Methods. Ali patients received FK506 beginning the 
day before transplantation at a dose of 0.03 mg/kg per 
day by continuous intravenous (IV) infusion. MTX was 
administered at a dose of 10 mg/m2 IV on day 1, and 7 
mg/m2 on days 3, 6, and 11. Intravenous administration 
of mPSL was started at a dose of 2 mg/kg per day on 
